What this pack is
Lumigan is the brand name in this record; bimatoprost is the generic name. Read both together with the dosage form (ophthalmic product).
PACK CHECK · MARKET FIRST
LumiganGeneric namebimatoprost
Mainland China pack-name cue卢美根®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The DailyMed label describes bimatoprost as a structural prostamide analogue with ocular-hypotensive activity and states that it is believed to increase aqueous-humour outflow through trabecular-meshwork and uveoscleral pathways. This explains a pharmacologic pathway; it does not determine anyone's cause of eye pressure, suitability, drop count, combination or switching plan.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 卢美根®
- International brand name
- Lumigan
- Generic name
- bimatoprost
- Dosage-form class
- Ophthalmic solution: 0.01% (0.1 mg/mL); this dossier displays the exact 5 mL fill in a 10 mL container, NDC 0023-3205-05
- Route
- Ophthalmic use
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:卢美根®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A percentage or mg/mL describes the labelled concentration of this exact eye product. It does not calculate an individual's number of drops, timing, missed-use action, combination or switch.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v19 (published 28 Jul 2026)
0.01% (0.1 mg/mL); 5 mL fill in a 10 mL container
- Product code
- NDC 0023-3205-05
- Form and route
- LUMIGAN bimatoprost ophthalmic solution · ophthalmic
- Labelled concentration
- 0.01% (0.1 mg/mL)Product identity, not an individual dose
- Container
- 10 mL dropper bottle · 5 mL
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- bimatoprost
- 0.1 mg/mLlabelled concentration; not an individual drop count
- Package
- 1 bottle per carton
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
LUMIGAN label reading: 0.01%, 0.1 mg/mL and 5 mL are different identity fields
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the U.S. DailyMed public label to check LUMIGAN, bimatoprost, 0.01%/0.1 mg/mL, the exact 5 mL container panel and ophthalmic use. It does not provide an individual's drop count, timing, missed-use handling, combination, switching or eye-pressure-management plan.
- 0.01% and 0.1 mg/mL are two label formats for the concentration of this eye-drop solution; 5 mL is the fill volume of this exact panel and 10 mL is the stated container size. They help identify the product, not calculate how many drops anyone should use, how long it lasts or whether to make up use.
- Eye drops cannot be self-combined, alternated or substituted merely because they mention glaucoma, eye pressure or prostaglandins. The label has product-specific checks involving other prostaglandin eye products, other drops and contact lenses; have an ophthalmologist or pharmacist review the actual bottles and complete eye/systemic medicine list.
- The package image, NDC, fill volume and container size only help compare a source. They cannot authenticate a product, identify another bimatoprost package or confirm current storage and handling requirements. Any opening, storage, spacing from another eye drop, contact-lens or missed-use question must follow the current label and professional instructions for the exact product in hand.
- The label includes warnings about iris, eyelid/eyelash changes, intraocular inflammation, macular oedema and bacterial keratitis. With vision change, marked eye pain, redness/swelling, injury or another acute eye concern, use local ophthalmic or urgent-care pathways promptly; this page does not decide self-continuation, pause or switching.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. LUMIGAN bimatoprost public label (Allergan; SPL v19, published 28 Jul 2026) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Lumigan (bimatoprost). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Lumigan is the brand in this record and bimatoprost is the active-ingredient name. Check both with the dosage form (Ophthalmic solution: 0.01% (0.1 mg/mL); this dossier displays the exact 5 mL fill in a 10 mL container, NDC 0023-3205-05) and the market on the actual pack.
Read the labelled strength in context
A percentage, mg/mL or pack volume describes the labelled eye-product identity. It is not an individual drop count, frequency or after-opening instruction.
Check the exact eye product
For an eye product, verify the exact concentration, bottle and current label. Do not transfer liquid between containers or treat a similar name as proof that products are interchangeable.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How bimatoprost works: the label describes an association with aqueous-humour outflow pathways
- “Associated with aqueous-humour outflow” explains a pharmacologic pathway, not a basis for deciding a need for treatment from symptoms, one pressure value or bottle appearance. Glaucoma and ocular-hypertension assessment still requires an eye examination, the current label and professional judgement.
- A shared prostaglandin-related eye-product description does not make LUMIGAN self-combinable, alternatable, substitutable or concentration-convertible with another drop. The complete eye/systemic medicine list, actual products, prior eye reactions and examination plan need professional review together.
- A mechanism page cannot turn “lowers eye pressure” into personal management for blurred vision, pain, redness, before/after procedures or sudden vision change. With an acute or serious eye concern, prioritise local ophthalmic and urgent medical support rather than self-adjusting from this page.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. LUMIGAN bimatoprost public label (Allergan; SPL v19, published 28 Jul 2026) ↗reviewed 2026-08-20
- FDA: LUMIGAN 0.01% NDA 022184 original application approval letter (31 Aug 2010) ↗Historical public record · reviewed 2026-08-20
- FDA: LUMIGAN 0.03% NDA 021275 historical approval administrative material (2001; not the 0.01% panel on this page) ↗Historical public record · reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Lumiganbimatoprost
This page links to public primary-source material for Lumigan. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Historical original approval for LUMIGAN 0.03%
FDA Drugs@FDA records approval of the original 0.03% application, NDA 021275, on 16 Mar 2001. This node only distinguishes it from the 0.01% panel on this page; it does not merge the concentrations or packages.
FDA: LUMIGAN 0.03% NDA 021275 historical approval materials (2001) ↗LUMIGAN 0.01% NDA 022184 original application approval
The FDA Drugs@FDA public record lists original application ORIG 1 for 0.01% as approved on 31 Aug 2010; this is the regulatory node for the exact 0.01% panel on this page.
FDA: LUMIGAN 0.01% NDA 022184 original approval letter (2010-08-31) ↗Current SPL v19 published on DailyMed
DailyMed lists 28 Jul 2026 as the Published Date for current LUMIGAN SPL v19; it does not establish actual marketing, stock or another-market status.
DailyMed: current LUMIGAN 0.01% public label, SPL v19 ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 卢美根®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.